Axonics® to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8
In conjunction with the release, the Company will host a conference call
with the investment community that same day at
Interested parties may access the live call via telephone by dialing (866) 687-5771 (U.S.) or (409) 217-8725 (International) and using passcode 7475517.
A live webcast of the call may be accessed by visiting the Events & Presentations page of the investors section of the Company's website at ir.axonicsmodulation.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company's website for 90 days.
Axonics, based in Irvine, CA, is focused on the development and
commercialization of a novel implantable SNM system for patients with
urinary and bowel dysfunction. The Axonics r-SNM® System is
the first rechargeable Sacral Neuromodulation system approved for sale
in Europe, Canada and Australia. Premarket approval for the r-SNM System
is currently pending with the
Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6320
President & Chief Financial Officer
Investor & Media Contact
Matt Clawson, +1-949-370-8500